Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Seaport Therapeutics, Inc. Common Stock (SPTX)
Boston, MA, US
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2025 actual |
Dec 2026 3 EPS Ana. |
Dec 2027 3 EPS Ana. |
Dec 2028 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
—
— – —
|
50.00M
50.00M – 50.00M
|
50.00M
50.00M – 50.00M
+0.0% YoY
|
| EBITDA |
-85.89M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-87.29M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-74.88M
est: -449.79M (+83.4%)
|
-239.87M
-281.80M – -197.95M
+46.7% YoY
|
-93.70M
-99.31M – -88.09M
+60.9% YoY
|
-97.91M
-123.77M – -72.06M
-4.5% YoY
|
-67.63M
-67.63M – -67.63M
+30.9% YoY
|
-102.41M
-102.41M – -102.41M
-51.4% YoY
|
| SGA |
20.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.94
est: -11.64 (+83.3%)
|
-6.22
-7.29 – -5.12
+46.6% YoY
|
-2.42
-2.57 – -2.28
+61.0% YoY
|
-2.53
-3.20 – -1.86
-4.5% YoY
|
-1.75
-1.75 – -1.75
+30.9% YoY
|
-2.65
-2.65 – -2.65
-51.4% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.59% | 1.26M | 0.50% |
| 2 | Schwab U.S. Small-Cap ETF SCHA | 0.01% | 1.46M | 0.03% |
| 3 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 14.1K | 0.06% |
| 4 | Vanguard Russell 2000 ETF VTWO | 0.00% | 140.4K | 0.06% |
| 5 | Schwab U.S. Broad Market ETF SCHB | 0.00% | 255.5K | 0.03% |
| 6 | Vanguard Extended Market ETF VXF | 0.00% | 322.7K | 0.05% |
| 7 | Vanguard Russell 3000 ETF VTHR | 0.00% | 2.8K | 0.06% |
| 8 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.1K | 0.03% |
| 9 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.8K | 0.17% |
| 10 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 425.06 | 0.17% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
